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Summary
Introduction and goal: Proinflammatory cytokines and prostaglandin E2 (PGE2) play an important role in the pathophysiology of osteolysis
and implant loosening. The aim of this study was to evaluate the role of pharmacological agents in the inhibition of Interleukin-1 (IL-1),
interleukin-6 (IL-6) and tumor necrosis factor- (TNF-) and PGE2 in explants of interface membranes from failed total hip replacements(fTHR).
Material and methods: Membranes from fTHR were retrieved (N=20) and explants were incubated for 72 h in the absence or presence of
tenidap at three different concentrations (5, 20 or 50 g/ml) or diclofenac (125 g/l). IL-1, IL-6, TNF-, and PGE2 levels were measured in
the culture medium using ELISA Capture or EIA kits. Statistical analysis was done using the Mann–Whitney U-test.
Results: A statistically significant inhibition in IL-1 synthesis was found at tenidap concentrations of 20 g/ml (71.3%, P<0.05) and 50 g/ml
(79.3%, P<0.02). Tenidap reduced IL-6 levels by 90.4% at 20 g/ml (P<0.005) and 96.0% (P<0.05) at 50 g/ml. Tenidap also reduced the
synthesis of TNF- by 66.9% (P<0.05) and 77.4% at concentrations of 20 g/ml and 50 g/ml. Tenidap had a marked suppressive effect of
over 90% (P<0.0001) on PGE2 synthesis in all three concentrations. Diclofenac (125 g/l) decreased PGE2 production by 95% (P<0.0001),
but had no significant effect in IL-1, IL-6, and TNF- levels in the culture medium.
Conclusion: The ability to simultaneously suppress the release of proinflammatory cytokines and PGE2 may help control osteolysis and
prevent aseptic loosening of THR. This effect could increase implant longevity and lead the way to the pharmacological treatment of this
pathology. © 2002 Published by Elsevier Science Ltd on behalf of OsteoArthritis Research Society International.
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Total hip replacement (THR) is the procedure of choice for
patients over the age of 60 suffering from osteoarthritis
(OA). Approximately 240 000 THR are performed every
year in the US and Canada, and roughly 10% of these
surgeries are revisions due to aseptic loosening. The
pathophysiology of osteolysis in failed THR (fTHR) is
related to a heavy macrophage response to implant debris
at the bone–implant interface and the expression of several
cytokines, namely tumor necrosis factor (TNF-), inter-
leukin (IL)-1 and IL-6, prostaglandins (PG), metallo-
proteinases (MMP) and nitric oxide (NO). Moreover, most
data in the literature have shown that the failure process is
likely to have multifactorial causes, including prosthetic
design, metal alloy debris, stress shielding, cement debris
and more recently polyethylene wear debris1–3.
Abundant wear debris and macrophages are found
within membranes and synovial fluid surrounding loosened
total hip prosthesis4. It has also been demonstrated that898macrophages could differentiate directly into osteoclastic
bone resorbing cells5, although the main pathway to
macrophage differentiation into osteoclasts responsible
for bone resorption in fTHR seems to be osteoblast-
dependent6.
To date, there is no effective treatment other than a
revision surgery for patients with fTHR due to aseptic
loosening. Understanding the pathophysiology of osteo-
lysis and the identification of the key modulators of the
inflammatory cascade generated by wear debris in recent
years has paved the way to potential pharmacological
treatment of THR failure7. Although still experimental, these
studies demonstrate that a new era in the prevention
and treatment of osteolysis and THR failure is starting8,9.
Several drugs which inhibit prostaglandin synthesis have
been examined in OA and wear debris-mediated osteo-
lysis10. In OA, tiaprofenic acid showed modest activity11,
diclofenac was inactive12, naproxen may affect some bio-
chemical parameters13, and aspirin accelerated the devel-
opment of severe OA14. In a wear debris model of
osteolysis, indometacin increased TNF- expression by
three-fold7, while pentofilin15 and ethanercept16 inhibited
TNF- expression and the progression of experimental
osteolysis.
Tenidap is an experimental antirheumatic drug of the
oxindole class17. This drug has a dual action—inhibiting
cyclooxygenases18 and the production of proinflammatory
cytokines such as IL-1, IL-6 and TNF- in human cell19,
synovial membrane explants from rheumatic arthritis
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PATIENT CHARACTERISTICS
Interface membrane specimens were obtained from the
proximal femur at Gruen zones I and VII29 at the time of
surgery from 20 patients undergoing revision procedures
for clinical failure of total hip arthroplasty (Table I). All
patients had a failed hybrid THR with a metal on ultra high
molecular weight polyethylene (UHMWPE) bearing in order
to minimize individual variability due to different wear
debris.
The indication for a revision included pain and evidence
of loosening. The presence of radiolucent lines at the bone
interface and the migration of a component according to
radiographic data confirmed loosening. The radiographs
from the loose implants with osteolysis contained one or
more areas showing ballooning and radiolucent zones with
scalloped edges adjacent to the cement mantle or bone.
Twelve patients were men and eight were women. They
all had a diagnosis of OA at the time of their primary THR.
The mean age (61.7±5.6 years, 65.4±5.6 years old,
mean±S.E.M., respectively) and the time to revision (57.0±
12.9 months, 49.2±11.5 months, mean±S.E.M., respec-tively) for both men and women were similar. In all patients,
both clinical and radiographic appearances were of aseptic
prosthetic failure. Infection cases were excluded by clinical
history and microbiology confirmation.
This study was approved by the Institutional Research
Committee/Institutional Ethics Committee of the Centre
hospitalier de l’Universite´ de Montre´al.Table I
Patients’ characteristics and type of failure
*fTHR—cavitary osteolysis fTHR—linear osteolysis
Patient
Age/
sex
Months to
revision
Type of
failure Patient
Age/
sex
Months to
revision
Type of
failure
MP 75/F 34 Cavitary osteolysis TM 71/F 34 THR dislocation/linear osteolysis
AJP 79/F 86 Cavitary osteolysis MB 78/F 118 Linear osteolysis
RB 77/M 54 Massive linear/cavitary osteolysis TK 68/M 62 Linear osteolysis
AL 68/F 40 Massive cavitary osteolysis/femoral fracture GR 42/F 38 Linear osteolysis/periprosthetic fracture
DDL 63/F 64 Linear/cavitary osteolysis AP 62/M 49 Linear osteolysis/periprosthetic fracture
TB 59/M 49 Massive cavitary osteolysis JP 59/M 41 Massive liner wear/linear osteolysis
JPP 79/F 86 Cavitary osteolysis AO 79/M 119 Linear osteolysis
PT 62/M 64 Linear/cavitary osteolysis PJ 61/M 49 Linear osteolysis
JMP 74/M 44 Linear/cavitary osteolysis MD 72/M 39 Linear osteolysis/fracture
AB 58/M 49 Massive cavitary osteolysis SO 69/M 41 Linear osteolysis
All patients had a diagnosis of hip osteoarthritis at the time of the primary total hip replacement. Only failed hybrid THR with metal on
UHMWPE bearings were included in the study to standardize patient selection.
*fTHR: Failed total hip replacement.EXPLANT CULTURE
Each interface membrane was aseptically dissected
from underlying bone and rinsed in cold saline solution.
Tissue samples were sectioned into small fragments of
4–5 mm in diameter. Explants weighing roughly 250 mg
were processed, randomly divided, and cultured in dupli-
cate in 12-well plates (Costar, Cambridge, MA, U.S.A.) with
4 ml Dulbecco modified Eagle’s medium (DMEM, GIBCO-
Life Technologies, Burlington, ON, Canada), containing
penicillin and streptomycin sulfate (100 U/ml and 100 g/
ml, respectively; GIBCO). No serum was present in the
culture medium20. Pilot studies were performed at
24 h, 48 h, and 72 h incubation to determine the ideal
experimental conditions. Cultures were incubated at
37°C for 72 h in a humidified 5% CO2/95% air mixture in
the absence or presence of tenidap ([Z]-5-chloro-2, 3
dihydro-3-[hydroxy-2-thienyl methylene]–oxo-1H-indole-1-
carboxamide, sodium salt) (Pfizer Central Research,
Groton, CT, U.S.A.) at final concentrations of 5, 20 or
50 g/ml or diclofenac sodium (Sigma-Aldrich, St Louis,
MO, U.S.A.) at final concentration of 125 g/l. The ideal
therapeutic plasma level in patients is 20 g/ml for
tenidap30. The concentration of diclofenac used in the
present in vitro experiments was similar to therapeutic
levels found in plasma and synovial fluid after oral admin-
istrations of the drug in humans31.
Tenidap and diclofenac were dissolved in ethanol and
further diluted to achieve the required final concentrations.
In each incubation well, the ethanol concentration did not
exceed 0.1% (V/V). For each specimen, there were appro-
priate controls for ethanol. At the end of the incubation
period, explants were weighed to normalize cytokine and
PGE2 levels as per gram of tissue wet weight (gww)32, and
the culture medium was collected and stored at −80°C until
further use20.patients20,21, and on a dog model of OA12. Tenidap has
been demonstrated to be an effective drug in the treatment
of rheumatoid arthritis22–24. In vivo, this drug was shown to
be capable of reducing, in arthritic patients, several biologi-
cal markers of inflammation and IL-619,21,22. The effect of
tenidap on CRP and SAA proteins is likely related to the
suppression of cytokine synthesis19,21,25. The relevance of
tenidap’s action as a cytokine modulating agent vis-a`-vis
osteolysis is most interesting as several reports have
indicated that, at the clinical stage of the disease, variable
degrees of inflammation are present26,27 and that interface
membranes in failed THR synthesize an increased amount
of IL-1, IL-6, TNF- and PGE228.
The aim of this study was to evaluate the efficacy of
simultaneous inhibition of cytokines and PGE2 in response
to tenidap, a potent cytokine modulator, in explants of
interface membranes from failed total hip arthroplasties,
and to compare their effect with diclofenac, a currently used
non-steroidal antiinflammatory drug (NSAID).
900 P. Lavigne et al.: Cytokine inhibition by tenidap in explants from failed THRCYTOKINE (IL-1, IL-6 AND TNF-) DETERMINATION
The levels of IL-1, IL-6 and TNF- were determined in
the culture medium of membrane explants by a capture
antibody in a sandwich enzyme-linked immunosorbent
assay (ELISA Capture)33. The IL-1, IL-6 Kit and TNF-
(high sensitivity) were obtained from R&D Systems,
(Minneapolis, MN, U.S.A.). Each ELISA was performed
according to the manufacturer’s specification. Sensitivity to
the culture medium was 0.3 pg/ml for IL-1, 3 pg/ml for IL-6
and 4.4 pg/ml for TNF-.PGE2 DETERMINATION
PGE2 was measured in the explant culture supernatants
using the PGE2 Immunoassay kit (Cayman Chemical, Ann
Arbor, Michigan, U.S.A.). This assay is based on the
competition between PGE2 and a PGE2-acetylcholin-
esterase conjugate (PGE2 tracer) for a limited amount of
PGE2 monoclonal antibody33.
All reactions were measured on a micro-ELISA Vmax
photometer (Molecular Devices Corp., Menlo Park, CA,
USA). Data were expressed in ng/g tissue wet weight
(ng/gww, IL-6 or PGE2) or pg/g tissue wet weight (pg/gww,
IL-1 or TNF-)32.STATISTICAL ANALYSIS
Twenty patients were included in this study (N=20).
Each membrane explanted from a given patient was tested
for every experimental condition. To avoid discrepancies in
cytokine and PGE2 levels when working with explants, two
samples of the same membrane were cultured for every
experimental condition and the mean result was included in
the statistical analysis as the only corresponding data for a
given patient. Therefore, our statistical analysis was based
on 20 separate results for each variable (N=20). Mean
values and standard errors of the mean were calculated,
and statistical analysis was done using the Mann–Whitney
U-test. P values equal or less than 0.05 were considered
significant.ResultsCYTOKINE AND PGE2 SYNTHESIS IN EXPLANTS
Preliminary experiments were carried out using revision
interface membranes explants, and the levels of inflamma-
tory mediators were measured. Cytokine levels over vari-
ous lengths of incubation time were also measured, and the
optimal incubation time was found to be 72 h.
At first, we examined the level of cytokine and PGE2
synthesis in membrane specimens of loosened implant
with osteolysis. The membrane explants produced IL-1,
IL-6, TNF- and PGE2. Cytokine and PGE2 production
varied considerably between patient samples. The secre-
tion of IL-1 (194.72±52.47 pg/gw, mean±S.E.M.) and
TNF- (4.04±0.70 pg/gww, mean±S.E.M.) were in the pico-
gram range, while the levels of IL-6 (183.34±110.04 ng/
gww, mean±S.E.M.) and PGE2 (791.53±310.99 ng/gww,
mean±S.E.M.) were in the nanogram range.Fig. 1. Levels of interleukin-1 (IL-1) in the culture medium of
interface membrane explants. Failed total hip replacement (fTHR)
interface membranes were retrieved at the time of revision surgery
(N=20) and explants were done as described in Material and
methods. The levels of IL-1 were determined in the culture
medium using ELISA capture and expressed as picograms of IL-1
per gram of tissue wet weight (pg/Gww). Explants from fTHR
treated with tenidap had a significant decrease in IL-1 levels
compared to untreated controls. There was no significant decrease
in IL-1 levels in the diclofenac-treated group when compared to
untreated controls. Values are expressed as the mean±S.E.M. and
statistical analysis was done by two-tailed Mann–Whitney U-test.EFFECTS OF DRUGS ON CYTOKINES AND PGE2
IL-1 was detected on all the specimens used. As shown
in Fig. 1, a statistically significant decrease in the IL-1synthesis was found at two tenidap concentrations tested;
with inhibition of 71.3% (P<0.05) at a therapeutic (20 g/
ml) concentration and 79.3% (P<0.02) at a supra-
therapeutic concentration (50 g/ml). Although the level of
IL-1 in the tenidap-treated specimens was reduced by
51.0% at a concentration of 5 g/ml, these results are not
statistically different from the untreated (control) speci-
mens. Diclofenac (125 g/l) had no significant effect on the
inhibition of IL-1 synthesis.
The interface membrane explants produced a very high
level of IL-6 compared with the two other cytokines studied
(IL-1 and TNF-). Our results showed that tenidap, at a
sub-therapeutic concentration (5 g/ml), reduced IL-6 pro-
duction by 77.5%, but there was no significant difference
with the control group (Fig. 2). The reduction was statisti-
cally significant at 90.4% (P<0.005) and 96.0% (P<0.05) at
20 g/ml and 50 g/ml, respectively. The level of IL-6 in
diclofenac-treated explants was similar to that in the
control.
We could only detect TNF- levels in the specimens with
a high sensitivity ELISA kit. The levels of TNF- protein
were relatively small compared with the other two cytokines
(IL-1 and IL-6) tested. The level of TNF- in the speci-
mens treated with 5 g/ml tenidap was slightly higher than
the control. In the presence of tenidap, a reduction of
synthesis of 66.9% (P<0.05) and 77.4% was noted at
concentration of 20 g/ml and 50 g/ml. There was no
statistically significant difference between 20 g/ml and the
control. The level of TNF- in the diclofenac-treated
explants (125 g/l) was not changed compared to the
untreated control (Fig. 3).
A significant level of PGE2 was present in all interface
membranes. Tenidap had a marked and significant sup-
pressive effect at all three concentrations used (5 g/ml,
20 mg/ml and 50 g/ml, respectively) on PGE synthesis.2
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tissues examined. Similarly, diclofenac significantly inhib-
ited (P<0.0001) PGE2 production at the interface mem-
branes by 95% using therapeutic concentrations of the
drug (125 g/l) (Fig. 4).Fig. 2. Levels of interleukin-6 (IL-6) in the culture medium of
interface membrane explants. Failed total hip replacement (fTHR)
interface membranes were retrieved at the time of revision surgery
(N=20) and explants were done as described in Material and
methods. The levels of IL-6 were determined in the culture medium
using ELISA Capture and expressed as nanograms of IL-6 per
gram of tissue wet weight (ng/Gww). There was no significant
decrease in IL-6 levels in the diclofenac-treated group when
compared to untreated controls. Values are expressed as the
mean±S.E.M. and statistical analysis was done by two-tailed Mann–
Whitney U-test.Fig. 3. Levels of tumor necrosis factor- (TNF-) in the culture
medium of interface membrane explants. Failed total hip replace-
ment (fTHR) interface membranes were retrieved at the time of
revision surgery (N=20) and explants were done as described in
Material and methods. The levels of TNF- were determined in the
culture medium using ELISA Capture (high sensitivity) and
expressed as picograms of TNF- per gram of tissue wet weight
(pg/Gww). (R&D Systems Minneapolis, MN, U.S.A.). Values are
expressed as the mean±S.E.M. and statistical analysis was done by
two-tailed Mann–Whitney U-test.Fig. 4. Level of prostaglandin E2 (PGE2) in the culture medium
interface membrane explants. Failed total hip replacement (fTHR)
interface membranes were retrieved at the time of revision surgery
(N=20) and explants were done as described in Material and
methods. The amount of PGE2 was assessed in the medium by
use of a PGE2 enzyme immunoassay kit and expressed as
nanograms of PGE2 per gram of tissue wet weight (ng/Gww).
Values are expressed as the mean±S.E.M. and statistical analysis
was done by two-tailed Mann–Whitney U-test.Discussion
This study shows that tissue retrieved from fTHR synthe-
sized significant levels of proinflammatory cytokines andPG. Indeed, high levels of PGE2, IL-1, IL-6 and TNF-
were synthesized by the tissue surrounding loose implant
with osteolysis. This phenomenon suggests that numerous
cytokines and other proinflammatory mediators are pro-
duced by bone and interface membranes of loosened
prosthesis and that specific cytokines, namely IL-1, IL-6
and TNF- are associated with osteolysis34. We have run
preliminary assays at 24 h, 48 h and 72 h in a pilot study to
address the question whether tissue extracts should have
been used instead of culture medium after 72 h incubation
in order to detect fine differences in our in vitro system.
TNF- was not detectable in significant levels prior to 72 h
incubation in the culture medium and, yet, a TNF- high-
sensitivity kit from R & D Systems (Minneapolis, U.S.A.)
had to be used. Moreover, IL-1 levels were also at the
picogram range at 72 h. Since TNF- is considered to be
the single most important cytokine implicated in wear-
debris induced osteolysis35–37, it seems logical that the
other cytokines and PGE2 should also be measured at
72 h. Our group has already successfully measured
cytokine levels in the culture medium of RA synovial
membranes explants at 72 h incubation with consistent
results20.
This corroborates the numerous studies that suggest
the excess synthesis and secretion of proinflammatory
cytokines from macrophages stimulated with wear particles
play a major role in the pathophysiology of osteolysis and
loosening process38,39. Cytokines exert their action by
binding to specific cell membrane receptors and transduc-
ing intracellular signals. IL-1 and TNF- are very potent
inducers of proteolytic enzymes, such as MMP, which can
destroy the interface tissues and remove osteoid, thereby
promoting osteolysis and providing a surface for osteo-
clastic bone resorption2,4,28. IL-6 is also implicated in the
modulation of bone resorption by the osteoclasts40. The
level of IL-6 was found in synovial fluid to be 10 times
higher in revision total joint arthroplasties with osteolysis
than those without osteolysis2. There is higher cytokine
expression in tissues surrounding cemented prostheses
when compared to prostheses without cement28. The
excess synthesis of PGE2 by interface membranes at the
site of aseptic loosening is also one of the factors contrib-
uting to osteolysis and the loosening process34,41–43.
902 P. Lavigne et al.: Cytokine inhibition by tenidap in explants from failed THROur results demonstrate that tenidap significantly inhib-
ited the expression of several cytokines from 67% up to
90% in therapeutic concentrations. The inhibition of TNF-
by tenidap was between 66.9% and 77.4% (P<0.05)
depending on the concentration used and that of IL-1 was
between 71% (P<0.05) and 79% (P<0.02). Moreover, the
level of IL-6 production was reduced by 90.4% (P<0.005) at
the lower tenidap concentration and by 96.0% (P<0.05) at
the higher concentrations. Tenidap also had a marked
suppressive effect of over 90% (P<0.0001) on PGE2
synthesis at all three concentrations used.
Tenidap, a drug from the chemical class of the oxindoles,
has been shown to modulate cytokine (IL-1, IL-6 and
TNF-) production in synovial membrane of RA patients20.
Tenidap also reduced in vivo IL-1 activity in synovial fluid
as well as the activity and/or expression of MMP in cartilage
in a canine experimental model44. Tenidap was chosen for
this study because of its very potent cytokine synthesis
inhibition both in vitro20 and in vivo44. On the other hand,
diclofenac, a NSAID belonging to the arylakanoic groups of
phenylacetic acid, significantly inhibited the synthesis of
PGE2, a major factor associated with the pathophysi-
ology and symptoms of osteolysis and implant loosening.
However, no effects were observed on the synthesis
of cytokines, which are known to be very important
modulators of osteolysis in periprosthetic tissues.
Much of the work to find a pharmacological treatment for
aseptic loosening has focused on bisphosphonates and
TNF- antagonists15,16,45,46. The potential of TNF- antag-
onists has already been demonstrated in an animal model
in osteolysis16. Thus, the reduction in TNF- production by
tenidap should have a similar effect on osteolysis preven-
tion. Also, the production of IL-6 and PGE2 by particle-
activated osteoblasts is thought to negatively influence the
gene expression of procollagen and favor recruitment of
osteoclastic cells34,41. The inhibition of PGE2 observed in
this study was not associated to a concomitant decrease in
cytokine levels in the diclofenac group. PGE2 is directly
related to IL-6 expression47 . Significantly suppressing
PGE2 by 95% from 0 h to 72 h using either drug has most
likely downplayed the increased levels of IL-6 found in the
culture medium. Nevertheless, a significant inhibition of
PGE2 should have also theoretically decreased IL-6 levels
in the diclofenac group, which was not the case. Contrary to
diclofenac, tenidap also seemed to have a direct inhibitory
effect on IL-1, IL-6 and TNF-, which explains its efficacy
even at 72 h of incubation compared to PGE2 inhibition
alone. The reduction of IL-6 and PGE2 secretion by teni-
dap could help restore the normal balance between bone
formation and bone resorption in implant failure.
The interaction between osteoblasts, macrophages and
osteoclasts in aseptic loosening of orthopedic implants is
underestimated in the literature. However, accumulating
evidence suggests that the osteoblasts play a central role
in recruiting and activating cells responsible for bone
destruction1,3,41,42. Modulation not only of proinflammatory
cytokines but also PGE2 synthesis by pharmacological
agents is of prime importance in avoiding orthopedic
implant loosening and osteolysis37,43,48.
Our findings suggest a possible role for multiple cytokine
inhibition in the treatment/prevention of patients suffering
from aseptic loosening. To our knowledge, this is the first
time that simultaneous inhibition of multiple cytokines and
PG in the interface membrane by a pharmacological agent
has been reported. Further studies in vivo are necessary to
evaluate the simultaneous inhibition of these proinflamma-
tory cytokines in the pathophysiology of implant loosening,as well as its correlation to osteoblastic activity40. These
findings pinpoint specific targets for potential pharmaco-
logical prevention of failed total joint arthroplasties and
provide alternatives to surgical treatment.Acknowledgments
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